Levetiracetam Accord

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
21-06-2023
Karakteristik produk Karakteristik produk (SPC)
21-06-2023

Bahan aktif:

levetiracetam

Tersedia dari:

Accord Healthcare S.L.U.

Kode ATC:

N03AX14

INN (Nama Internasional):

levetiracetam

Kelompok Terapi:

Antiepileptics,

Area terapi:

Epilepsy

Indikasi Terapi:

Levetiracetam is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Ringkasan produk:

Revision: 16

Status otorisasi:

Authorised

Tanggal Otorisasi:

2011-10-03

Selebaran informasi

                                36
B. PACKAGE LEAFLET
37
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
LEVETIRACETAM ACCORD 250 MG FILM-COATED TABLETS
LEVETIRACETAM ACCORD 500 MG FILM-COATED TABLETS
LEVETIRACETAM ACCORD 750 MG FILM-COATED TABLETS
LEVETIRACETAM ACCORD 1000 MG FILM-COATED TABLETS
Levetiracetam
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU OR YOUR CHILD START
TAKING THIS MEDICINE BECAUSE IT
CONTAINS IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes, any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Levetiracetam Accord is and what it is used for
2.
What you need to know before you take Levetiracetam Accord
3.
How to take Levetiracetam Accord
4.
Possible side effects
5.
How to store Levetiracetam Accord
6.
Contents of the pack and other information
1.
WHAT LEVETIRACETAM ACCORD IS AND WHAT IT IS USED FOR
Levetiracetam Accord is an antiepileptic medicine (a medicine used to
treat seizures in epilepsy).
Levetiracetam Accord is used:

on its own in adults and adolescents from 16 years of age with newly
diagnosed epilepsy, to
treat a certain form of epilepsy. Epilepsy is a condition where the
patients have repeated fits
(seizures). Levetiracetam is used for the epilepsy form in which the
fits initially affect only
one side of the brain but could thereafter extend to larger areas on
both sides of the brain
(partial onset seizure with or without secondary generalisation).
Levetiracetam has been given
to you by your doctor to reduce the number of fits.

as an add-on to other antiepileptic medicines to treat:
-
partial onset seizures with or without generalisation in adults,
adolescents, children
and infants from one month of age;
-
myoclonic seizures (short, s
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Levetiracetam Accord 250 mg film-coated tablets
Levetiracetam Accord 500 mg film-coated tablets
Levetiracetam Accord 750 mg film-coated tablets
Levetiracetam Accord 1000 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Levetiracetam Accord 250 mg film-coated tablets
Each film-coated tablet contains 250 mg levetiracetam
Levetiracetam Accord 500 mg film-coated tablets
Each film-coated tablet contains 500 mg levetiracetam
Levetiracetam Accord 750 mg film-coated tablets
Each film-coated tablet contains 750 mg levetiracetam
Excipient with known effect:
Each film-coated tablet contains 0.013 mg of sunset yellow FCF (E110)
Levetiracetam Accord 1000 mg film-coated tablets
Each film-coated tablet contains 1000 mg levetiracetam
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
The tablet can be divided into equal halves
Levetiracetam Accord 250 mg film-coated tablets
White to off white, oval, biconvex, debossed ‘L 64’ and break line
on one side and plain on the other
side
Levetiracetam Accord 500 mg film-coated tablets
Yellow coloured, oval, biconvex, debossed ‘L 65’ and break line on
one side and plain on the other
side.
Levetiracetam Accord 750 mg film-coated tablets
Pink coloured, oval, biconvex, debossed ‘L 66’ and break line on
one side and plain on the other side.
Levetiracetam Accord 1000 mg film-coated tablets
White to off white, oval, biconvex, debossed ‘L 67’ and break line
on one side and plain on the other
side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Levetiracetam is indicated as monotherapy in the treatment of partial
onset seizures with or without
secondary generalisation in adults and adolescents from 16
years of age with newly diagnosed
epilepsy.
3
Levetiracetam is indicated as adjunctive therapy

in the treatment of partial onset seizures with or without secondary
generalisation in adults,
adolescents, children and infants from 1 month 
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 21-06-2023
Karakteristik produk Karakteristik produk Bulgar 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Bulgar 10-09-2021
Selebaran informasi Selebaran informasi Spanyol 21-06-2023
Karakteristik produk Karakteristik produk Spanyol 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Spanyol 10-09-2021
Selebaran informasi Selebaran informasi Cheska 21-06-2023
Karakteristik produk Karakteristik produk Cheska 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Cheska 10-09-2021
Selebaran informasi Selebaran informasi Dansk 21-06-2023
Karakteristik produk Karakteristik produk Dansk 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Dansk 10-09-2021
Selebaran informasi Selebaran informasi Jerman 21-06-2023
Karakteristik produk Karakteristik produk Jerman 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Jerman 10-09-2021
Selebaran informasi Selebaran informasi Esti 21-06-2023
Karakteristik produk Karakteristik produk Esti 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Esti 10-09-2021
Selebaran informasi Selebaran informasi Yunani 21-06-2023
Karakteristik produk Karakteristik produk Yunani 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Yunani 10-09-2021
Selebaran informasi Selebaran informasi Prancis 21-06-2023
Karakteristik produk Karakteristik produk Prancis 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Prancis 10-09-2021
Selebaran informasi Selebaran informasi Italia 21-06-2023
Karakteristik produk Karakteristik produk Italia 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Italia 10-09-2021
Selebaran informasi Selebaran informasi Latvi 21-06-2023
Karakteristik produk Karakteristik produk Latvi 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Latvi 10-09-2021
Selebaran informasi Selebaran informasi Lituavi 21-06-2023
Karakteristik produk Karakteristik produk Lituavi 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Lituavi 10-09-2021
Selebaran informasi Selebaran informasi Hungaria 21-06-2023
Karakteristik produk Karakteristik produk Hungaria 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Hungaria 10-09-2021
Selebaran informasi Selebaran informasi Malta 21-06-2023
Karakteristik produk Karakteristik produk Malta 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Malta 10-09-2021
Selebaran informasi Selebaran informasi Belanda 21-06-2023
Karakteristik produk Karakteristik produk Belanda 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Belanda 10-09-2021
Selebaran informasi Selebaran informasi Polski 21-06-2023
Karakteristik produk Karakteristik produk Polski 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Polski 10-09-2021
Selebaran informasi Selebaran informasi Portugis 21-06-2023
Karakteristik produk Karakteristik produk Portugis 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Portugis 10-09-2021
Selebaran informasi Selebaran informasi Rumania 21-06-2023
Karakteristik produk Karakteristik produk Rumania 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Rumania 10-09-2021
Selebaran informasi Selebaran informasi Slovak 21-06-2023
Karakteristik produk Karakteristik produk Slovak 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Slovak 10-09-2021
Selebaran informasi Selebaran informasi Sloven 21-06-2023
Karakteristik produk Karakteristik produk Sloven 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Sloven 10-09-2021
Selebaran informasi Selebaran informasi Suomi 21-06-2023
Karakteristik produk Karakteristik produk Suomi 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Suomi 10-09-2021
Selebaran informasi Selebaran informasi Swedia 21-06-2023
Karakteristik produk Karakteristik produk Swedia 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Swedia 10-09-2021
Selebaran informasi Selebaran informasi Norwegia 21-06-2023
Karakteristik produk Karakteristik produk Norwegia 21-06-2023
Selebaran informasi Selebaran informasi Islandia 21-06-2023
Karakteristik produk Karakteristik produk Islandia 21-06-2023
Selebaran informasi Selebaran informasi Kroasia 21-06-2023
Karakteristik produk Karakteristik produk Kroasia 21-06-2023
Laporan Penilaian publik Laporan Penilaian publik Kroasia 10-09-2021

Peringatan pencarian terkait dengan produk ini